

## Special Issue

# CAR T Cells in Lymphoma and Multiple Myeloma

### Message from the Guest Editors

Cellular therapies, including chimeric antigen receptor (CAR) T cell therapy and bispecific antibodies (BiTE), have changed the treatment landscape for lymphomas and multiple myeloma. These treatments are primarily used in the relapsed or refractory setting, although exploration in early lines of therapy is under investigation in clinical trials. Despite exciting outcomes, there are a number of challenges that remain. Examples include poor T cell expansion and short-term T cell persistence, leading to suboptimal response and/or relapse. The purpose of this Special Issue is to understand how to decrease the toxicity and increase the efficacy of CAR T cell therapy in patients with lymphoma or multiple myeloma.

---

### Guest Editors

Dr. Javier Munoz

Division of Hematology, Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA

Dr. Julia Erin Wiedmeier-Nutor

Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA

---

### Deadline for manuscript submissions

31 January 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/167808](https://mdpi.com/si/167808)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)